dry macular degeneration
Selected indexed studies
- Treatment of dry age-related macular degeneration: A review. (Clin Exp Ophthalmol, 2023) [PMID:37737509]
- LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System. (Retina, 2024) [PMID:37972955]
- Treatment for dry age-related macular degeneration: where we stand in 2024. (Curr Opin Ophthalmol, 2024) [PMID:38869976]
_Worker-drafted node — pending editorial review._
Connections
dry macular degeneration is caused by
Sources
- Treatment of dry age-related macular degeneration: A review. (2023) pubmed
- LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System. (2024) pubmed
- Treatment for dry age-related macular degeneration: where we stand in 2024. (2024) pubmed
- Innovative technologies for the treatment of dry age-related macular degeneration (AMD) - modern therapeutic perspectives and their future. (2025) pubmed
- A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION. (2020) pubmed
- Safety and tolerability of RPESC-RPE transplantation in patients with dry age-related macular degeneration: Low-dose clinical outcomes. (2025) pubmed
- Dry and neovascular "wet" age-related macular degeneration: Upcoming therapies. (2025) pubmed
- C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. (2021) pubmed
- Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions. (2022) pubmed
- The intersection of mitochondria, lipids, and ferroptosis: a new avenue for dry age-related macular degeneration. (2025) pubmed